MX2023009423A - Composiciones senoliticas y usos de las mismos. - Google Patents

Composiciones senoliticas y usos de las mismos.

Info

Publication number
MX2023009423A
MX2023009423A MX2023009423A MX2023009423A MX2023009423A MX 2023009423 A MX2023009423 A MX 2023009423A MX 2023009423 A MX2023009423 A MX 2023009423A MX 2023009423 A MX2023009423 A MX 2023009423A MX 2023009423 A MX2023009423 A MX 2023009423A
Authority
MX
Mexico
Prior art keywords
diseases
disorders
prevented
treated
side effects
Prior art date
Application number
MX2023009423A
Other languages
English (en)
Inventor
Mark A Gallop
Marco Quarta
Julian Klein
Original Assignee
Rubedo Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubedo Life Sciences Inc filed Critical Rubedo Life Sciences Inc
Publication of MX2023009423A publication Critical patent/MX2023009423A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H99/00—Subject matter not provided for in other groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proporcionan agentes senolíticos para eliminar selectivamente células senescentes que se encuentran asociadas con numerosas patologías y enfermedades, incluidas patologías y enfermedades relacionadas con la edad. Como se describe en la presente, las enfermedades y trastornos asociados a células senescentes pueden tratarse o prevenirse mediante la administración de al menos un agente senolítico o composiciones farmacéuticas del mismo. Las enfermedades o trastornos asociados a las células senescentes tratados o prevenidos por los métodos descritos en la, presente incluyen, pero no se limitan a, enfermedades o trastornos cardiovasculares, enfermedades y trastornos cardiovasculares asociados con arteriosclerosis, tales como aterosclerosis, fibrosis pulmonar idiopática (IPF) enfermedad pulmonar obstructiva crónica (COPD), osteoartritis, enfermedades o trastornos inflamatorios, enfermedades o trastornos autoinmunes, enfermedades o trastornos pulmonares, enfermedades o trastornos neurológicos, enfermedades o trastornos dermatológicos, efectos secundarios de la quimioterapia, efectos secundarios de la radioterapia, metástasis y enfermedades metabólicas.
MX2023009423A 2018-07-11 2021-01-11 Composiciones senoliticas y usos de las mismos. MX2023009423A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862696486P 2018-07-11 2018-07-11

Publications (1)

Publication Number Publication Date
MX2023009423A true MX2023009423A (es) 2023-08-23

Family

ID=69140375

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021000395A MX2021000395A (es) 2018-07-11 2019-07-11 Composiciones senolíticas y usos de las mismas.
MX2023009423A MX2023009423A (es) 2018-07-11 2021-01-11 Composiciones senoliticas y usos de las mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021000395A MX2021000395A (es) 2018-07-11 2019-07-11 Composiciones senolíticas y usos de las mismas.

Country Status (10)

Country Link
US (3) US11026963B2 (es)
EP (1) EP3790861A4 (es)
JP (2) JP7444797B2 (es)
KR (1) KR20210030905A (es)
CN (1) CN112469697A (es)
CA (1) CA3105982A1 (es)
IL (1) IL279755A (es)
MX (2) MX2021000395A (es)
SG (1) SG11202012099VA (es)
WO (1) WO2020014409A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202008201D0 (en) * 2020-06-01 2020-07-15 Neophore Ltd Inhibitor compounds
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
WO2023039292A2 (en) * 2021-09-13 2023-03-16 Rubedo Life Sciences, Inc. Novel sugar derivatives and uses thereof to prepare novel senolytic agents
WO2023039600A1 (en) * 2021-09-13 2023-03-16 Rubedo Life Sciences, Inc. Drug conjugates of sugar derivatives and uses thereof as senolytic agents
CN114249782B (zh) * 2022-01-05 2023-06-30 湖南大学 一种选择性破坏衰老细胞溶酶体的前药及其制备方法与应用
WO2024036961A1 (zh) * 2022-08-19 2024-02-22 北京三秀生物医药科技有限公司 一种抗衰老相关疾病的前药及其使用方法
CN116942653A (zh) * 2023-08-25 2023-10-27 徐诺药业(南京)有限公司 艾贝司他用于制备防治细胞因子风暴相关疾病药物的用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US6664443B1 (en) 1998-05-01 2003-12-16 Mayo Foundation For Medical Education And Research Pathogenic Tau mutations in transgenic mice
EP1231919B1 (en) 1999-09-08 2015-09-30 Sloan-Kettering Institute For Cancer Research Derivatives of 1-amino-1-(hetero)arylaminocarbonyl-6-hydroxyaminocarbonylhexane useful in the treatment of tumors
CN1257190C (zh) 2003-04-02 2006-05-24 郭全太 聚葡萄糖生产工艺
CA2672192A1 (en) 2006-12-19 2008-06-26 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
US7939544B2 (en) * 2007-09-25 2011-05-10 Abbott Laboratories Octahydropentalene compounds as chemokine receptor antagonists
US20110053991A1 (en) * 2007-11-19 2011-03-03 Gore Lia Treatment of Histone Deacetylase Mediated Disorders
US8278436B2 (en) * 2008-07-30 2012-10-02 Wisconsin Alumni Research Foundation Glycosylated warfarin analogs and uses thereof
US8859566B2 (en) * 2009-03-13 2014-10-14 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
US20120005765A1 (en) 2010-07-01 2012-01-05 Saint Louis University Animal model for parkinson's disease
BR112013003847A8 (pt) 2010-08-19 2017-12-26 Buck Institute For Age Res métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados
EP2616470B1 (en) * 2010-09-13 2016-10-12 Advinus Therapeutics Limited Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
MX2014007093A (es) 2011-12-13 2014-10-13 Buck Inst For Res On Aging Metodos para mejorar terapias medicas.
CN104185564B (zh) 2012-03-29 2018-12-04 飞利浦灯具控股公司 加热装置
TR201901651T4 (tr) 2012-08-28 2019-02-21 Univ Tuebingen Medizinische Fakultaet Yaşlanma izleyicileri.
TW201536324A (zh) 2013-06-19 2015-10-01 Buck Inst For Res On Aging 增加醫藥療法有效性之方法
CA3100140C (en) 2014-01-28 2023-10-24 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
EP3139942B1 (en) 2014-05-05 2019-12-18 Bioventures, Llc COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
SG11201702483QA (en) * 2014-09-29 2017-04-27 Scripps Research Inst Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders
US20180021323A1 (en) 2015-01-22 2018-01-25 Bioventures, Llc Flip - a selective molecular target of senescent cells
JP2018508569A (ja) * 2015-02-06 2018-03-29 ユニティ バイオテクノロジー インコーポレイテッド 老化関連状態の治療における化合物および使用
KR102447884B1 (ko) * 2016-04-21 2022-09-27 바이오벤처스, 엘엘씨 항-세포자멸적 bcl-2 계열 단백질의 열화를 유도하는 화합물 및 이의 용도
WO2018146506A1 (en) 2017-02-10 2018-08-16 Universitat Politècnica De València Therapeutic derivatives

Also Published As

Publication number Publication date
JP7444797B2 (ja) 2024-03-06
US11026963B2 (en) 2021-06-08
CN112469697A (zh) 2021-03-09
US20200016185A1 (en) 2020-01-16
MX2021000395A (es) 2021-05-12
EP3790861A4 (en) 2022-03-30
JP2024059789A (ja) 2024-05-01
WO2020014409A1 (en) 2020-01-16
KR20210030905A (ko) 2021-03-18
JP2021531249A (ja) 2021-11-18
SG11202012099VA (en) 2021-01-28
CA3105982A1 (en) 2020-01-16
US20230321130A1 (en) 2023-10-12
US20210299154A1 (en) 2021-09-30
EP3790861A1 (en) 2021-03-17
IL279755A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
MX2023009423A (es) Composiciones senoliticas y usos de las mismos.
SG10201805670QA (en) Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
MX2021009673A (es) Moduladores de ror-gamma.
MD4658B1 (ro) Inhibitori ai kinazei inductoare de apoptoză
PH12017500635B1 (en) Aminopyridyloxypyrazole compounds
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
WO2017132432A8 (en) Benzimidazole derivatives as modulators of ror-gamma
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2015008090A (es) Compuestos de piridina-2-carboxamida sustituida como inhibidores de cinasa reguladora de señal de apoptosis.
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
NZ712479A (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
MX2012015105A (es) Inhibidores de cinasa de regulacion mediante señal de apoptosis.
UA111767C2 (uk) Дигідропіримідинізохінолінони і фармацевтичні композиції, які їх містять, для лікування запальних порушень
NZ709803A (en) Compositions comprising 15-ohepa and methods of using the same
PH12016502447A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
MX2018006635A (es) Agonistas del receptor 2 de formilpeptido y del receptor 1 de formilpeptido, de piperidinona.
MX2019006495A (es) Tratamiento de enfermedades neurologicas.
NZ739867A (en) Aminonaphthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
MX371178B (es) Orvepitant para el tratamiento de la tos crónica.
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
WO2016168388A3 (en) Therapies for obesity, diabetes and related indications